Quantum Immunologics, a Major Mentor Capital Investee, Starts FDA-Authorized Breast Cancer Trials

(For Immediate Release, July 15, 2009)

SAN DIEGO, Mentor Capital, Inc. (Pink Sheets: MNTR) announces that Quantum Immunologics, Inc. (QI), has met a significant milestone marking the beginning of its FDA-authorized breast cancer trial, the completion of the first clinical treatment injection.

Mentor Capital, Inc. is the largest single shareholder in QI and looks to provide equity funding throughout the trials, assist QI in funding future strategic stock or cash acquisitions, and to stand by as a preferred funding source for QI during later stage or additional trials. Calculated at the current QI private placement price, Mentor Capital holds approximately $3.74 in QI stock per Mentor share, and QI represents the majority of Mentor Capital’s portfolio assets.

Quantum Immunologics is based in Tampa, Florida and focuses on cancer immunotherapies. This research and development company is currently sponsoring and conducting an FDA-authorized Phase I/II clinical trial testing the safety and efficacy of its immunotherapy on twenty-seven Stage IV breast cancer patients who have failed conventional therapy. The first patient in the breast cancer trial has begun to receive QI’s dendritic cell therapy. According to Mr. Chuck Broes, CEO of QI, “This achievement marks a significant milestone in the life cycle of our company, and we look forward with great hope and commitment as we aspire to a successful trial outcome.”

Chet Billingsley, CEO of Mentor Capital adds, “The successful initiation of concurrent Phase I/II trials represents an important step in the value equation for QI. Comparing the cost to acquire 20% of other dendritic immunotherapy companies, like Dendreon (DNDN), with Mentor Capital, which holds 20% of QI, will reveal attractive buying opportunities for biotechnology investors, now that QI is at the clinical stage.”

QI’s clinical trial is designed around the use of QI’s proprietary dendritic cell therapy, which employs oncofetal antigen (OFA) to recruit the patient’s own immune system to target and attack the cancer cells with the intent to improve patient survivability and quality of life. Each patient will receive three monthly injections of the patient’s own dendritic cells that have been sensitized to OFA. It is anticipated that once the sensitized cells are injected back into the patient, the patient’s T-cells will locate the OFA found on the patient’s cancer cells, thereby generating an immune response with the goal of killing the cancer cells and preventing further spread of the disease.

Further information on Quantum Immunologics, including a summarizing video of the QI breast cancer treatment methodology that is now in FDA trials, may be found at their company web site: www.QuantumImmunologics.com. Comprehensive information on Mentor Capital, including capital structure detail, can be found at: www.MentorCapital.com. Level II quotes, news, financial information and trading charts may be referenced at www.PinkSheets.com under the trading symbol MNTR.

Forward Looking Statements, Safe Harbor and Risk Descriptions are

Incorporated by Reference from the MNTR Company Web Site above.

For further information contact:

Chet Billingsley, CEO

Mentor Capital, Inc.

P.O. Box 1709

Ramona, CA 92065 (760) 788-4700

Quantum Immunologics, Inc.

22202 N. West Shore Blvd., Suite 200

P.O. Box 20727

Tampa, Florida 33623 (813) 849-7859